Skip Navigation

Adalvo announces successful DCP submission for Lisdexamfetamine Oral Solution

07 October 2021

Adalvo is delighted to announce the successful submission of our DCP procedure for Lisdexamfetamine Oral Solution 10mg / ml which has been developed in close collaboration with Laboserve & Pharma-Data.

This value-added version of Lisdexamfetamine comes in the form of a taste-masked, ready-to-use oral solution. Our product is a child-friendly, re-purposed version of Elvanse®, a CNS drug that is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The brand (together with its US sister-brand that is called Vyvanse®) currently sells over $4 billion across the globe. Beyond patient compliance our product is also patent protected both in EU and US.

We are the only known company who is targeting a differentiated child-friendly version of this product which will dramatically increase the patient value and demonstrates our ability to continuously offer highly differentiated, value-added products to our partners